Organon & Co Dossier
Qualitative Analysis
Business overview
Organon & Co. (NYSE: OGN) is a global healthcare company dedicated to improving the health of women throughout their lives. Spun off from Merck & Co. in June 2021, Organon operates with a diverse portfolio of prescription therapies and medical devices. The company's business is structured around three core pillars: Women's Health (including contraception and fertility brands like Nexplanon and Follistim), Biosimilars (spanning immunology and oncology treatments), and Established Brands (a highly diversified portfolio of well-known, off-patent medicines across cardiovascular, dermatology, and pain management areas). Organon serves drug wholesalers, retailers, hospitals, and government agencies globally, with approximately half of its revenues generated outside the United States.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following the integration of Dermavant in the US, Organon is executing the international launch of VTAMA (tapinarof) cream, 1% to expand its medical dermatology footprint.
Expected impact: Aims to capture market share in the plaque psoriasis and atopic dermatitis markets, diversifying revenue beyond legacy established brands.
Expanding the biosimilars portfolio in collaboration with Samsung Bioepis, focusing on rolling out Hadlima (adalimumab), Ontruzant (trastuzumab), and Aybintio (bevacizumab).
Expected impact: Aims to achieve mid-teens market share in key molecules and reduce reliance on legacy established brands.
Increasing commercial presence and patient pathways in the Asia-Pacific region, particularly China, to capture growing demand for reproductive health services.
Expected impact: Targeting an increase in the fertility-related revenue mix by 200 to 300 basis points by 2027.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition adds VTAMA (tapinarof) cream, 1%, an FDA-approved non-steroidal topical therapy, accelerating Organon's entry into the high-growth medical dermatology space.
Financial impact: Includes an upfront payment of $175 million, a $75 million milestone paid upon FDA approval for atopic dermatitis, and up to $950 million in sales-based milestones.
Strategic Partnerships
Organon obtained exclusive global commercial rights to MIUDELLA, a hormone-free copper intrauterine device (IUD) approved by the FDA in February 2025.
Terms: Organon will pay $27.5 million at closing, with potential sales-based milestone payments of up to $505 million, plus tiered double-digit royalties on net sales.
Organon acquired the U.S. commercial and regulatory rights for Tofidence (tocilizumab), an FDA-approved biosimilar indicated for rheumatoid arthritis and other inflammatory conditions.
Terms: Organon agreed to pay an upfront payment of $51 million (paid in July 2025), plus tiered royalties and annual sales milestones of up to $45 million.